Changeflow GovPing Healthcare & Life Sciences Natera Patent Application on Xenotransplant Rej...
Routine Notice Added Final

Natera Patent Application on Xenotransplant Rejection Detection Methods

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

Natera, Inc. has filed US Patent Application US20260110032A1 disclosing methods for detecting and monitoring xenotransplant rejection by extracting and measuring cell-free DNA, RNA, or proteins derived from the xenotransplant in recipient biological samples. The methods enable rejection assessment through sequencing library preparation and whole genome sequencing analysis of donor-derived biomarkers. Transplant centers, biotech researchers, and diagnostics developers in the organ transplantation space should monitor this intellectual property filing.

“The present disclosure provides methods for preparation and analysis of biological samples of xenotransplant recipients, wherein the methods comprise extracting fragmented or intact cell-free DNA, RNA (such as mRNA or miRNA), or protein derived from sample of the xenotransplant recipient, and measuring amounts of cell-free DNA, RNA (such as mRNA or miRNA), or protein derived from the xenotransplant enables assessment of xenotransplant rejection.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.

What changed

Natera, Inc. filed US Patent Application US20260110032A1 covering methods for detecting and monitoring xenotransplant rejection through analysis of donor-derived cell-free DNA, RNA (including mRNA or miRNA), or protein biomarkers extracted from recipient biological samples. The detection of cell-free DNA or RNA may be performed by preparing sequencing libraries and performing whole genome sequencing. The application was filed on September 27, 2023, and published April 23, 2026.

Affected parties include transplant centers, biotechnology companies developing organ transplantation diagnostics, and clinical researchers focused on xenotransplant monitoring. While this is a patent application rather than an issued patent, companies engaged in cell-free DNA-based transplant monitoring technologies should review the scope of these claims as they advance toward potential grant.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS FOR DETERMINATION AND MONITORING OF XENOTRANSPLANT REJECTION BY MEASURING NUCLEIC ACIDS OR PROTEINS DERIVED FROM THE XENOTRANSPLANT

Application US20260110032A1 Kind: A1 Apr 23, 2026

Assignee

Natera, Inc.

Inventors

Tudor Pompiliu CONSTANTIN, Bernhard ZIMMERMANN, Gabrielle HEILEK, Swee Seong WONG

Abstract

The present disclosure provides methods for preparation and analysis of biological samples of xenotransplant recipients, wherein the methods comprise extracting fragmented or intact cell-free DNA, RNA (such as mRNA or miRNA), or protein derived from sample of the xenotransplant recipient, and measuring amounts of cell-free DNA, RNA (such as mRNA or miRNA), or protein derived from the xenotransplant enables assessment of xenotransplant rejection. The detection of the cell-free DNA, or RNA may be performed by preparing sequencing libraries and performing whole genome sequencing.

CPC Classifications

C12Q 1/6883 C12N 9/226 C12N 15/1096 C12N 15/111 C12Q 1/37 C12Q 1/6806 C12Q 1/6809 C12Q 1/6848 C12Q 1/6874 C12N 2310/20 C12Q 2600/106 G01N 2333/922

Filing Date

2023-09-27

Application No.

19117608

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260110032A1

Who this affects

Applies to
Clinical investigators Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent examination IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!